Regulatory Filings • Apr 7, 2008
Regulatory Filings
Open in ViewerOpens in native device viewer
155 boulevard Haussmann 75008 Paris (France) Phone + 33(0)145 64 44 60 Fax +33(0)145 64 44 64 e-mail: [email protected] www.cerep.com
PerkinElmer, Inc. 940 Winter Street Waltham, MA 02451 (USA) Phone: +1 (781) 663 6900 Fax: +1 (781) 663 5985 www.perkinelmer.com
Supply and co-marketing agreement provides biotechnology and pharmaceutical customers with a total solution for drug candidate detection and validation
Paris, France, April 7, 2008 – news release 2008/06
PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, and Cerep SA (Eurolist: Cerep), a leading provider of drug candidate screening and profiling technologies, today announced the signing of a supply and co-marketing agreement to deliver custom drug discovery services. Under the terms of the agreement, PerkinElmer will exclusively market Cerep's target screening and profiling services to its customers, and the companies will jointly promote PerkinElmer's assay technologies and Cerep services to the drug discovery market.
"This agreement represents the latest step in our strategy to build the most comprehensive offering in biochemical and cellular screening for drug discovery", said Robert F. Friel, President and Chief Executive Officer, PerkinElmer, Inc. "Our customers will benefit from direct access to Cerep's expertise in high throughput screening and profiling services, while PerkinElmer will be able to extend the reach of our leading assay technologies and assay development services into key drug discovery markets."
"Cerep is committed to providing the highest quality services in drug discovery and drug development and we are pleased to work with an established leader of drug discovery technologies to further strengthen our offerings", said Thierry Jean, Chairman and Chief Executive Officer, Cerep. "This agreement with PerkinElmer enables us to support our customers' complete drug discovery needs, from assay design to target screening and profiling, by adding a range of enabling assay technologies to our drug screening and profiling services."
This agreement provides PerkinElmer customers with an option to work with a single vendor throughout the entire drug discovery process. Cerep customers will now have access to several key assay development and detection platforms from PerkinElmer's Bio-discovery business, including AlphaScreen®, AlphaLISA™, LANCE®, and LANCE® Ultra™ for G protein-coupled receptor (GPCR) and kinase assay development.
GPCRs and protein kinases represent a wide range of therapeutic targets in areas including cancer, central nervous system disorders, cardiac dysfunction, and diabetes, making them among the most important areas of study in today's pharmaceutical and biotech laboratories.
Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the company's Document de référence.
Communiqué
News release
Cerep's mission is to provide pharmaceutical companies with high quality services in drug discovery and drug development. Cerep provides, both in Europe and in the United States, solutions allowing faster and cost effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development.
Additional information is available through www.cerep.com.
Thierry Jean, Chairman & CEO Michèle Arnoe, Global Head, Business Development Tel. +33 (0)1 45 64 44 60 [email protected]
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of \$1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index.
Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
Investor relations: Michael A. Lawless, +1 (781) 663 5659 Media contact: Stephanie Wasco, +1 (203) 402 1700
Code ISIN FR0004042232 Euronext Paris Eurolist - Valeurs locales
Cerep SA 155 boulevard Haussmann 75008 Paris France tel + 33(0)145 64 44 60 fax +33(0)145 64 44 64 e-mail: [email protected] www.cerep.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.